The Greatest Wealth is Health - spectaris.de€¦ · The Greatest Wealth is Health Smart Drug...
15
The Greatest Wealth is Health Smart Drug Discovery Ludwigshafen, 08.05.2019 Dr. Simon Widmaier CEO and Co-Founder Aquarray GmbH Overcoming the limitations of state-of-the-art biological experiments
Transcript of The Greatest Wealth is Health - spectaris.de€¦ · The Greatest Wealth is Health Smart Drug...
The Greatest Wealth is Health
Smart Drug DiscoveryLudwigshafen, 08.05.2019
Dr. Simon Widmaier CEO and Co-Founder Aquarray GmbH
Overcoming the limitations of state-of-the-art biological experiments
Why is screening important?
23.05.2019 Aquarray - Next Generation Screening 2
€ 105 B budget p.a.
Top 50 Pharma
Animal Models Human TrialsCell ScreeningResearch
10 B experiments p.a.
Drug Development
100 M animals p.a.
Organism Toxicity
59 NME in 2018 [FDA]
Approval
€ 550 B global cost p.a.
Alzheimer’s Disease
Flu, Ebola, new pathogens
Pandemics
[ 1500 drug molecules ]
FDA approvedTuberculosis, staph aureus
Anti-Biotic Resistance
18.1 M global cases p.a.
Cancer
Disruptive Technology Platform
23.05.2019 Aquarray - Next Generation Screening 3
4 international patents (US/EU/PCT) 5 pending patents (US/EU/PCT)2 patent applications (US/EU/PCT)
Biofunctional surface patterning
Based on semi-conductor production
Scalability
IP Portfolio
Droplet Microarray
Droplet Microarray
23.05.2019 Aquarray - Next Generation Screening 4
Commercialisation & Marketing Strategy
23.05.2019 Aquarray - Next Generation Screening 5
Engineering Partners
Value Chain Partners
Strengthen sales partnerships
Distribution in BRICS, EU, AU
2021
Direct sales
Distribution partnership: JP
2018
Awards
23.05.2019 Aquarray - Next Generation Screening 6
Science4Life Venture Cup 2017
• Idea phase
• Concept phase
Cytometry 2017
Science4Life Venture Cup 2018
• Business Plan phase
EIT Health Catapult 2018
Hello Tomorrow Global Top 500
Seal of Excellence by the European Commission
The Aquarray Team
23.05.2019 Aquarray - Next Generation Screening 7
Dr. Pavel LevkinCSO
Konstantin DemirProduction manager
Dr. Anna PopovaCTO
Dr. Simon WidmaierCEO
Prof. Dr. Dr. Gunter FestelFESTEL CapitalBusiness Angel
Prof. Jörg VienkenFresenius Medical Care
Scientific Advisor
Prof. Michael GrunzeUniversity Heidelberg
Scientific Advisor
Dr. Eric BraunKIT – IRM
Equity Manager
7 PhDs
5 FT employees
6 PT employees
100 years of combinedmanagement experience
Biotech/start-up expertise
Inventors
Scientists
Managers
Business-Angels
Advisors
Competence
Experience
Antimicrobial Compounds
23.05.2019 Aquarray - Next Generation Screening 8
Drug printed glass slides
DMA slides with bacterial droplets
Parallel addition of drug library
Wenxi Lei
GFP expressingPseudomonas Aeruginosa Pa01
0 µM 6 µM 60 µM 120 µM
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
OD
60
0
Concentration
in 96-well plate
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
on DMA surface
mean flu
ore
scent in
tensity p
er
pix
el
0 µM 1 µM 10 µM 40 µM
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
OD
60
0
Concentration
in 96-well plate
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
on DMA surface
mea
n f
luore
sce
nt
inte
nsity p
er
pix
el
0 µM 2 µM 20 µM 80 µM
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
OD
60
0
Concentration
in 96-well plate
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4 on DMA surface
mean flu
ore
scent in
tensity p
er
pix
el
Lei et al., Manuscriptin preparation
Workflow Results
Ciprofloxacin
Ceftazidime
Tobramycin
Parallel screening of antibiotics and drug combinations
100nL per droplet
Over 500 experiments per Droplet Microarray
Replacing pipetting by sandwiching
Microscopy read-out
Assay
Parallel screening of drug and transfection agent combinations
30nL per droplet
Over 2000 experiments per Droplet Microarray
Assay runtime < 48 h
Microscopy read-out
Transfection Enhancers
23.05.2019 Aquarray - Next Generation Screening 9
500 μm DMA slides
Image analysisGFP expression
Yanxi Liu
FDA approved drug library (774
compounds)
42,000
20nL
200
pmoles
2,500
times
per spot
drugs
less than 384-well plates
individualexperiments
WorkflowAssay
3D Cell Culture
23.05.2019 Aquarray - Next Generation Screening 10
0
0,005
0,01
0,015
0,02
0,025
0,03
0,035
50 100 150 200 250 300
Po
iss
on
Fu
ncti
on
0
0,005
0,01
0,015
0,02
0,025
0,03
0,035
0,04
50 100 150 200 250 300
Po
iss
on
Fu
ncti
on
Nanoliter dispensing
Manual seeding
Popova / manuscrip submitted
Dr. Anna Popova
Droplets stable against gravity -> hanging drop
Array of over 600 spheroids
By manual seeding (without automation)
By nanoliter dispensing
Controllable volumes and cell numbers
Assay
23.05.2019 Aquarray - Next Generation Screening 11
10 days7 days3 days2 days1 day
Calcein
PI
60 cells 150 cells 350 cells
60 cells 150 cells 350 cells
HE
K
29
3M
CF
7
Popova / manuscrip submitted
Controllable spheroid sizes: 60 – 350 cells
Cultivation times up to 7 days without medium exchange
Conventional calcein PI staining
Microscopic read-out
Wash off / yield easily
Assay
Comparison Results
Microwell plate
Droplet Microarray
23.05.2019 Aquarray - Next Generation Screening 12
Popova et al
Equivalent results:Dose-response
99% savings compared to gold standard 384 microwell plate
Validated with 30+ cell lines, primary cells, stem cells and zebra fish models
2D and 3D cell culture
Assay
Dr. Anna Popova
Applications and Publications
23.05.2019 Aquarray - Next Generation Screening 13
Biological Screenings
2D cell culture using cell lines
Primary cells
3D cell cultureSpheroids3D cell culture
Scaffolds/ hydrogels
Animal models
Stem cells
Tronser et al., Adv. HealthcareMater. 2017
Tronser et al., Lab Chip 2018
mESC-GFPmouse embryonic stem cells
Neto et al., Adv. Mater. 2016
Popova et al., Adv. Func. Mater. 2017
HEK293 cells Calcein
PI
Popova et al., Manuscriptsubmitted
Calcein stainingPopova et al., Manuscriptsubmitted
Popova et al., Adv. Mater. 2015Popova et al., RSC Advances 2016Popova et al., SLAS Technology 2017
Bacteria
Lei et al., Manuscriptsubmitted
Applications and Pilot Customers
23.05.2019 Aquarray - Next Generation Screening 14
Versatile cell screening:• Adherent/suspension cells/single cells• Primary cells• Stem cells
Compound screening:• Drug discovery• Toxicity screening
Screening using genetic perturbation:• Gene-overexpression• RNA interference• Gene editing (CRISPR/Cas9)
Screening in 3D cell culture:• Hydrogels• Spheroids
More screening at lower costs and predictive for human physiology that is:
Next Generation Screening
23.05.2019 Aquarray - Next Generation Screening 15
Dr. Simon Widmaier +49 721 608 23302
CEO & Co-Founder [email protected] +49 160 706 5757
